Adam Esbenshade, MD, MSCI

Adam Esbenshade, MD, MSCI

John N. Lukens, Jr. Chair in Pediatric Hematology and Oncology
Professor of Pediatrics
Preston Research Building
2220 Pierce Avenue
Room / Suite
(615) 936-1762

Hematology/Oncology, Pediatric
University of Tennessee at Memphis, Memphis, TN, 2004
Pediatrics Internship-University of Tennessee at Memphis, LeBonheur Children's Hospital, Memphis, TN
Pediatrics Residency-University of Tennessee at Memphis, LeBonheur Children's Hospital, Memphis, TN
Pediatrics Hematology/Oncology Fellowship-Vanderbilt University Medical Center, Nashville, TN

Clinical Interests

Pediatric Neuro-Oncology, Supportive Care, Infectious Complications of Cancer, Survivorship

Research Information

Dr. Esbenshade is a Pediatric Neuro-oncologist and Professor of Pediatrics. His research focuses on Cancer Control, Supportive Care, Central Nervous System Malignancy, and Cancer Survivorship. Areas of active investigation include risk prediction modeling and establishing evidence-based data for the treatment of infectious disease complications during pediatric cancer for which he has a current multi-institution prospective validation study. He is also working on studies to improve the treatment of obesity and the metabolic syndrome in cancer survivors, validating a comprehensive risk score that summarizes a cancer survivors' co-morbidities, as well as, clinical trials that focus on targeted therapy for CNS tumors. Dr. Esbenshade is a member of the Children's Oncology Group (COG) and is the Vice Chair of the COG Young Investigators Committee and Vice Chair of the COG Cancer Control and Supportive Care Committee. He also serves on the CNS committee and is on the national study committees of several COG trials. He is a member of the Society for Pediatric Research and is a member of the American Society of Pediatric Hematology Oncology (ASPHO) Conference Planning Committee. He is a member of the SIOP Young Investigators Education Committee and has helped to establish international mentorship programs in both SIOP and SIOP-Europe. As of 2020, will be a member of the Journal of Clinical Oncology Editorial Board.